Ingrid Skop, M.D., FACOG

CLI Director of Data Analytics Dr. James Studnicki and Director of Medical Affairs Dr. Ingrid Skop recently published their paper "Is Induced Abortion Evidence-Based Medical Practice?" in the journal Medical Research Archives. In the paper, Studnicki and Skop argue that there are objective criteria by which a given medical practice can be judged "evidence-based," and that abortion fails to meet these criteria.

CLI's VP of Medical Affairs Ingrid Skop, together with Calum Miller, MD, and Kevin Duffy, MPH, recently published an article in Issues in Law & Medicine arguing that decisions by the FDA to pull back regulations on the abortion drug mifepristone in part relied on "flawed studies with significantly undercounted complications" from the U.K.

Recently CLI scholars Ingrid Skop, M.D. and Mary Harned, J.D. published a rebuttal in Issues in Law & Medicine to a series of misleading statements made in an article that appeared in the journal Obstetrics & Gynecology.

The false claim that abortion is 14 times safer than childbirth arose from a 2012 journal article by two vocal abortion advocates, Elizabeth Raymond and David Grimes. Despite being debunked in the dozen years since, it continues to be repeated by pro-abortion media advocates. This issue of On Women's Health explains numerous reasons this statement is false and not data-driven.

It is a scientific fact that the embryo or fetus within the mother’s womb is a distinct human being, and, consequently, abortion ends the life of that human being.

If mifepristone is unavailable, patients will not suffer, for there are several other effective options available for treating a miscarriage. Fearmongering about an inability to treat miscarriages in the aftermath of Dobbs should be recognized for the ideologically driven, pro-abortion rhetoric that it is.

It is a scientific fact that the embryo or fetus within the mother’s womb is a distinct human being, and, consequently, abortion ends the life of that human being.

Opill, the first nonprescription oral contraceptive pill (OCP) to be granted FDA approval, is a synthetic progesterone (norgestrel) 0.075 mg tablet taken daily (with no placebo week). The following are important facts for women and physicians to know as Opill hits the market for the first time in 2024.

Most on the left vehemently oppose any legislative limits on abortion, and some on the right, even if they identify as pro-life, are of the opinion that a federal limit on late abortions would fail to find consensus and so could not be passed.

Limiting abortion will not prohibit any life-saving medical interventions, as is clearly shown by every pro-life state law having exceptions for the life of the mother.